金石亚药（300434.SZ）12月29日在投资者互动平台表示，公司自成立以来一直致力于增强塑料复合管 道全套生产工艺、技术解决方案及成套生产设备的研发、制造，为客户提供整厂方案规划、优质的设备 和服务，推动细分行业有序、健康、高质量发展。公司复合管道可应用于市政给排水、工业压力输送管 道、矿用耐磨管道、石油天然气集输管线等多种民用工业领域。近年来，公司重点推广的石油、天然气 工业用带式增强柔性复合管成套设备，以先进稳定的制造工艺和设备铆定国际市场并带动国内的应用试 点。2025年，该品类产品国内外的销售订单稳步上升，市场预期持续向好。 每经AI快讯，有投资者在投资者互动平台提问：公司的复合管道应用哪些领域？有没有量产？ （文章来源：每日经济新闻） ...

有投资者在互动平台向金石亚药提问："公司的复合管道应用哪些领域？有没有量产。" 针对上述提问，金石亚药回应称："尊敬的投资者，您好！公司自成立以来一直致力于增强塑料复合管 道全套生产工艺、技术解决方案及成套生产设备的研发、制造，为客户提供整厂方案规划、优质的设备 和服务，推动细分行业有序、健康、高质量发展。公司复合管道可应用于市政给排水、工业压力输送管 道、矿用耐磨管道、石油天然气集输管线等多种民用工业领域。近年来，公司重点推广的石油、天然气 工业用带式增强柔性复合管成套设备，以先进稳定的制造工艺和设备铆定国际市场并带动国内的应用试 点。2025年，该品类产品国内外的销售订单稳步上升，市场预期持续向好。感谢您的关注！" 来源：市场资讯 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 ...

即食人参是以人参为原料，经清洗、蒸煮、切片、干燥、调味等工艺加工制成的人参产品。即食人参无 需复杂加工、开袋或简单冲泡后可直接食用，它保留人参主要营养成分，同时解决传统人参食用不便、 口感苦涩的问题，满足便捷进补需求。目前，市面上常见的即食人参产品有人参液/饮、即食参片、人 参膏等。 市面上常见的即食人参产品介绍 二、发展历程 相关企业：上海领参科技有限公司、吉林靖宇炳华中药开发有限公司、康美新开河（吉林）药业有限公 司、杭州胡庆余堂药业有限公司、上海上药神象健康药业有限公司 关键词：即食人参行业发展历程、即食人参市场政策、即食人参产业链图谱、即食人参市场规模、即食 人参竞争格局、即食人参发展趋势 一、概述 内容概要：随着国民健康意识的不断提升、健康养生理念不断普及，不仅中老年群体重视人参的传统滋 补功效，高压白领、年轻消费者也开始关注抗疲劳、增强免疫等功能性产品，即食人参解决了传统人参 食用繁琐、口感苦涩的问题，适配日常通勤、办公间隙等多种场景，近年来消费群体不断增加，市场规 模也不断扩大，据统计，2024年我国即食人参行业市场规模达280亿元，同比增长14.3%。 相关上市企业：同仁堂（600085）、华 ...

证券日报网讯12月18日，金石亚药（300434）在互动平台回答投资者提问时表示，今幸胶囊是公司保健 食品领域重点产品之一，是CFDA审批的第一个人参皂苷Rh2单方产品，人参皂苷Rh2含量达到16.2%。 目前，该产品在天猫、京东等电商平台均有销售。今幸胶囊在今年的天猫双十一期间销售额排名人参热 销榜第一名。 ...

证券日报网讯12月12日，金石亚药（300434）在互动平台回答投资者提问时表示，公司在海南省设有两 家子公司，分别是海南亚洲制药股份有限公司和海南快克药业有限公司，均正常运营中。海南省现已出 台涉及产业扶持、关税减免、税收优惠、人才引进等多项政策。未来，公司也将密切关注政策动态，深 入研读政策细则，结合公司中长期战略，积极挖掘潜在商业机会，助力公司持续稳健发展。 ...

Group 1 - The flu-related concept has become active again, with Haiwang Bio hitting the daily limit up [2] - Yue Wannianqing has increased by over 12% [2] - Other companies such as Guangji Pharmaceutical, Hendi Pharmaceutical, Te Yi Pharmaceutical, Jinshi Yiyao, and Xinhua Pharmaceutical have also seen gains [2]

Core Viewpoint - The company Jinshi Yiyao (300434.SZ) is a leading brand owner of cold medicine products in China, specifically known for "Kuaike" and "Xiaokuaike" [1] Product Portfolio - The company has developed a product cluster focused on adult and pediatric cough relief over more than 20 years of brand accumulation [1] - Key products include: - "Kuaike" compound paracetamol and amantadine capsules for alleviating symptoms of common colds and influenza, also used for prevention and treatment of influenza [1] - "Xiaokuaike" pediatric paracetamol and chlorpheniramine granules for relieving symptoms of common colds and influenza in children [1] - "Kuaike Qing" oseltamivir phosphate capsules for treating and preventing type A and B influenza in adults and children aged 1 year and older [1] - Additional products include: - Yumeijia Mamin syrup, Pudilan anti-inflammatory tablets, antiviral oral liquid, compound honeysuckle granules, cold-clearing granules, ibuprofen granules, and various cough relief granules [1]

Core Viewpoint - The company Jinshi Yiyao (300434.SZ) is a leading brand owner of cold medicine products in China, specifically known for "Kuaike" and "Xiaokuaike" [1] Product Portfolio - The company has developed a product cluster focused on adult and pediatric cough relief over more than 20 years of brand accumulation [1] - Key products include: - "Kuaike" compound paracetamol and amantadine capsules for alleviating symptoms of common colds and influenza, also used for prevention and treatment of influenza [1] - "Xiaokuaike" pediatric paracetamol and chlorpheniramine granules for relieving symptoms of common colds and influenza in children [1] - "Kuaike Qing" oseltamivir phosphate capsules for treating and preventing type A and B influenza in adults and children aged one year and older [1] - Additional products include: - Yumeijia Mamin syrup, Pudilan anti-inflammatory tablets, antiviral oral liquid, compound honeysuckle granules, cold-clearing heat granules, ibuprofen granules, and various cough relief granules [1] - The product range meets diverse consumer needs for prevention, alleviation, and treatment of colds [1]

每经AI快讯，11月26日，流感概念反复活跃，广济药业3连板，北大医药触及涨停，金迪克涨超10%， 海南海药涨超7%，特一药业、新华制药、金石亚药跟涨。 （文章来源：每日经济新闻） ...

Group 1 - The stock of Jinshi Yao increased by 6.22%, closing at 12.81 yuan on November 25 [1] - A significant block trade occurred, with a total volume of 1 million shares and a transaction amount of 10 million yuan [1] - The first transaction price was 10.00 yuan for 1 million shares, resulting in a discount rate of -21.94% [1] Group 2 - In the past three months, the stock has recorded two block trades with a total transaction amount of 19.9 million yuan [1] - Over the last five trading days, the stock has risen by 6.84%, with a net inflow of main funds totaling 26.4953 million yuan [1]